Antinociceptive, hypoglycemic and spasmolytic effects of Brickellia veronicifolia

Francisco Palacios-Espinosa, Myrna Déciga-Campos, Rachel Mata

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: Brickellia veronicifolia (Kunth) Gray (Asteraceae) (BV) is broadly commercialized for treating gastrointestinal diseases (stomach aches, biliary colics and dyspepsia), arthritis, diabetes and painful inflammatory complaints. Aims of the study: In order to complete the preclinical pharmacological profile of BV, first the antinociceptive effect of an organic extract (BVE) and isolated metabolites on the hot plate and writhing tests was assessed. Experimental: Then, their potential hypoglycemic effects were analyzed in normoglycemic and diabetic rats; in addition, an oral glucose tolerance test (OGTT) was performed. Finally, the spasmolytic activity of BVE was assessed in vivo using the gastrointestinal motility test (GMT) in mice. Results: The results revealed that BVE (100-600 mg/kg), 6-methoxysalicylic acid (1), 2-methoxybenzoic acid (2), benzyl-2,6-dimethoxybenzoate (3), and taraxasteryl acetate (4) showed significant analgesic effects. Compounds 2 and 3 were the most active (1-100 mg/kg) in the hot plate and writhing tests, respectively. In the antidiabetic assays, BVE (100 mg/kg) showed an important hypoglycemic action. Furthermore, at the same dose, it provoked a significant postprandial decrease of blood glucose level after 30 min of a glucose challenge. Finally, the GMT in mice revealed the spasmolytic activity in vivo of BVE (31.6 mg/kg). Conclusion: The overall information tends to support the vernacular uses of the plant. © 2008 Elsevier Ireland Ltd. All rights reserved.
Original languageAmerican English
Pages (from-to)448-454
Number of pages402
JournalJournal of Ethnopharmacology
DOIs
StatePublished - 13 Aug 2008

Fingerprint

Parasympatholytics
Hypoglycemic Agents
Gastrointestinal Motility
Asteraceae
Colic
Gastrointestinal Diseases
Dyspepsia
Glucose Tolerance Test
Ireland
Arthritis
Analgesics
Blood Glucose
Stomach
Pharmacology
Glucose
Pain
Acids

Cite this

@article{e006641842cc4b5c95868dd259eb8622,
title = "Antinociceptive, hypoglycemic and spasmolytic effects of Brickellia veronicifolia",
abstract = "Introduction: Brickellia veronicifolia (Kunth) Gray (Asteraceae) (BV) is broadly commercialized for treating gastrointestinal diseases (stomach aches, biliary colics and dyspepsia), arthritis, diabetes and painful inflammatory complaints. Aims of the study: In order to complete the preclinical pharmacological profile of BV, first the antinociceptive effect of an organic extract (BVE) and isolated metabolites on the hot plate and writhing tests was assessed. Experimental: Then, their potential hypoglycemic effects were analyzed in normoglycemic and diabetic rats; in addition, an oral glucose tolerance test (OGTT) was performed. Finally, the spasmolytic activity of BVE was assessed in vivo using the gastrointestinal motility test (GMT) in mice. Results: The results revealed that BVE (100-600 mg/kg), 6-methoxysalicylic acid (1), 2-methoxybenzoic acid (2), benzyl-2,6-dimethoxybenzoate (3), and taraxasteryl acetate (4) showed significant analgesic effects. Compounds 2 and 3 were the most active (1-100 mg/kg) in the hot plate and writhing tests, respectively. In the antidiabetic assays, BVE (100 mg/kg) showed an important hypoglycemic action. Furthermore, at the same dose, it provoked a significant postprandial decrease of blood glucose level after 30 min of a glucose challenge. Finally, the GMT in mice revealed the spasmolytic activity in vivo of BVE (31.6 mg/kg). Conclusion: The overall information tends to support the vernacular uses of the plant. {\circledC} 2008 Elsevier Ireland Ltd. All rights reserved.",
author = "Francisco Palacios-Espinosa and Myrna D{\'e}ciga-Campos and Rachel Mata",
year = "2008",
month = "8",
day = "13",
doi = "10.1016/j.jep.2008.05.012",
language = "American English",
pages = "448--454",
journal = "Journal of Ethnopharmacology",
issn = "0378-8741",
publisher = "Elsevier Ireland Ltd",

}

Antinociceptive, hypoglycemic and spasmolytic effects of Brickellia veronicifolia. / Palacios-Espinosa, Francisco; Déciga-Campos, Myrna; Mata, Rachel.

In: Journal of Ethnopharmacology, 13.08.2008, p. 448-454.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antinociceptive, hypoglycemic and spasmolytic effects of Brickellia veronicifolia

AU - Palacios-Espinosa, Francisco

AU - Déciga-Campos, Myrna

AU - Mata, Rachel

PY - 2008/8/13

Y1 - 2008/8/13

N2 - Introduction: Brickellia veronicifolia (Kunth) Gray (Asteraceae) (BV) is broadly commercialized for treating gastrointestinal diseases (stomach aches, biliary colics and dyspepsia), arthritis, diabetes and painful inflammatory complaints. Aims of the study: In order to complete the preclinical pharmacological profile of BV, first the antinociceptive effect of an organic extract (BVE) and isolated metabolites on the hot plate and writhing tests was assessed. Experimental: Then, their potential hypoglycemic effects were analyzed in normoglycemic and diabetic rats; in addition, an oral glucose tolerance test (OGTT) was performed. Finally, the spasmolytic activity of BVE was assessed in vivo using the gastrointestinal motility test (GMT) in mice. Results: The results revealed that BVE (100-600 mg/kg), 6-methoxysalicylic acid (1), 2-methoxybenzoic acid (2), benzyl-2,6-dimethoxybenzoate (3), and taraxasteryl acetate (4) showed significant analgesic effects. Compounds 2 and 3 were the most active (1-100 mg/kg) in the hot plate and writhing tests, respectively. In the antidiabetic assays, BVE (100 mg/kg) showed an important hypoglycemic action. Furthermore, at the same dose, it provoked a significant postprandial decrease of blood glucose level after 30 min of a glucose challenge. Finally, the GMT in mice revealed the spasmolytic activity in vivo of BVE (31.6 mg/kg). Conclusion: The overall information tends to support the vernacular uses of the plant. © 2008 Elsevier Ireland Ltd. All rights reserved.

AB - Introduction: Brickellia veronicifolia (Kunth) Gray (Asteraceae) (BV) is broadly commercialized for treating gastrointestinal diseases (stomach aches, biliary colics and dyspepsia), arthritis, diabetes and painful inflammatory complaints. Aims of the study: In order to complete the preclinical pharmacological profile of BV, first the antinociceptive effect of an organic extract (BVE) and isolated metabolites on the hot plate and writhing tests was assessed. Experimental: Then, their potential hypoglycemic effects were analyzed in normoglycemic and diabetic rats; in addition, an oral glucose tolerance test (OGTT) was performed. Finally, the spasmolytic activity of BVE was assessed in vivo using the gastrointestinal motility test (GMT) in mice. Results: The results revealed that BVE (100-600 mg/kg), 6-methoxysalicylic acid (1), 2-methoxybenzoic acid (2), benzyl-2,6-dimethoxybenzoate (3), and taraxasteryl acetate (4) showed significant analgesic effects. Compounds 2 and 3 were the most active (1-100 mg/kg) in the hot plate and writhing tests, respectively. In the antidiabetic assays, BVE (100 mg/kg) showed an important hypoglycemic action. Furthermore, at the same dose, it provoked a significant postprandial decrease of blood glucose level after 30 min of a glucose challenge. Finally, the GMT in mice revealed the spasmolytic activity in vivo of BVE (31.6 mg/kg). Conclusion: The overall information tends to support the vernacular uses of the plant. © 2008 Elsevier Ireland Ltd. All rights reserved.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=47749118710&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=47749118710&origin=inward

U2 - 10.1016/j.jep.2008.05.012

DO - 10.1016/j.jep.2008.05.012

M3 - Article

C2 - 18583074

SP - 448

EP - 454

JO - Journal of Ethnopharmacology

JF - Journal of Ethnopharmacology

SN - 0378-8741

ER -